This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.

Inclusion criteria:

• Participant with essential hypertension
• Participant who is treated with COZAAR XQ within local label for the first time

Exclusion criteria:

• Participant who is treated with COZAAR XQ before contract and out of enrollment period
• Participant who has a contraindication to COZAAR XQ according to the local label

Participants with essential hypertension not adequately controlled with amlodipine or losartan monotherapy; initial therapy for participants with stage 2 hypertension